GLP-1受体激动剂-阿尔波特综合征的另一种有前途的治疗方法?
Jan Boeckhaus1, Holly Mabillard2,3, John A Sayer2,4,5
1Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.
Journal of rare diseases (Berlin, Germany)
|March 3, 2025
概括
类似葡萄糖-1受体激动剂对阿尔波特综合征,一种脏疾病显示出有前途. 需要进一步的研究来探索它们的保护作用和减缓患者功能衰竭的潜力.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 遗传学 遗传学是一种遗传学.
背景情况:
- 阿尔波特综合征 (AS) 是一种进展性遗传性病,导致功能衰竭.
- 目前的治疗方法提供有限的保护,需要新的治疗策略.
研究的目的:
- 对阿尔波特综合征中葡萄糖类-1受体激动剂 (GLP-1RA) 的治疗潜力进行审查.
- 探索GLP-1RA的脏保护作用背后的机制.
主要方法:
- 对病中GLP-1RAs的临床前和临床数据的综述.
- 分析潜在的作用机制,包括抗炎和抗纤维效应.
主要成果:
- GLP-1RA在2型糖尿病和慢性病中表现出心血管和脏保护作用.
- 有证据表明GLP-1 RAs可以减少白蛋白尿和减缓脏疾病的进展.
结论:
- GLP-1RA对阿尔波特综合征具有显著的治疗潜力.
- 需要进一步的临床试验来评估AS患者的GLP-1RA,以改善结果.
相关概念视频
Glucagon-like Receptor Agonists
290
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
290
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
142
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
142
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
Dipeptidyl Peptidase 4 Inhibitors
161
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
161
GPCRs Regulate Adenylyl Cylase Activity
5.1K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.1K
Oral Hypoglycemic Agents: Glinides
129
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
129


